EGFR and neoplasm: Here, we examined whether the PI3K/mTOR (both mTORC1 and mTORC2) inhibitors BEZ235 and NVP-BGT226 (BGT226) could sensitise tumor cells with EGFR overexpression or Ras mutation to radiation.